{
  "neuralace_development_phases": [
    {
      "phase": 1,
      "name": "Research Use Only (RUO)",
      "timeline": "2024-2025",
      "regulatory_status": "No FDA approval required",
      "description": "Distribution to neuroscience research community for non-clinical use",
      "requirements": [
        "Label device as 'For Research Use Only'",
        "Do not promote for clinical use",
        "IRB approval if used in human subjects research",
        "Material transfer agreements for academic partners"
      ],
      "target_customers": [
        "Academic neuroscience labs",
        "Research consortiums (e.g., BRAIN Initiative)",
        "Government research facilities",
        "Pharma R&D partners"
      ],
      "manufacturing_requirements": "GMP recommended but not required",
      "risks": [
        "Cannot make clinical claims",
        "Limited revenue potential",
        "Competitor research adoption"
      ]
    },
    {
      "phase": 2,
      "name": "Visual Prosthesis IDE",
      "timeline": "2026-2028",
      "regulatory_status": "IDE required for human clinical study",
      "description": "Early Feasibility Study for cortical visual prosthesis",
      "indication": "Severe to total blindness from visual pathway damage",
      "study_design": {
        "type": "Early Feasibility Study",
        "patients": "6-10",
        "follow_up_years": 5,
        "primary_endpoint": "Safety (SAEs, device-related AEs)",
        "secondary_endpoint": "Phosphene perception, functional vision"
      },
      "requirements": [
        "Preclinical biocompatibility studies",
        "Non-human primate efficacy data",
        "Full GMP manufacturing",
        "IRB and FDA IDE approval"
      ],
      "regulatory_precedent": {
        "device": "Orion Cortical Visual Prosthesis",
        "company": "Second Sight/Cortigent",
        "nct": "NCT03344848",
        "status": "Early Feasibility Study ongoing"
      }
    },
    {
      "phase": 3,
      "name": "Visual Prosthesis HDE Approval",
      "timeline": "2029-2031",
      "regulatory_status": "Humanitarian Device Exemption",
      "description": "Commercial approval for cortical visual prosthesis",
      "pathway_rationale": "Patient population <8,000/year qualifies for HDE",
      "hde_requirements": [
        "Demonstrate probable benefit outweighs risks",
        "Not required to demonstrate effectiveness",
        "IRB approval at each implanting institution",
        "Post-approval study possible"
      ],
      "precedent": {
        "device": "Argus II Retinal Prosthesis",
        "hde_number": "H110002",
        "approval_date": "2013-02",
        "indication": "Severe to profound retinitis pigmentosa"
      },
      "alternative_pathway": {
        "name": "PMA",
        "when": "If population exceeds HDE threshold or sponsor prefers",
        "additional_time_years": "2-3"
      }
    },
    {
      "phase": 4,
      "name": "Mental Health Applications",
      "timeline": "2030+",
      "regulatory_status": "Additional IDE studies required",
      "target_indications": [
        {
          "indication": "Treatment-Resistant Depression",
          "population_size_us": 3000000,
          "pathway": "PMA (too large for HDE)",
          "precedent": "DBS trials for depression (failed); TMS for depression (approved)"
        },
        {
          "indication": "Severe Treatment-Resistant OCD",
          "population_size_us": 50000,
          "pathway": "HDE possible",
          "precedent": "DBS for OCD HDE (2009)"
        },
        {
          "indication": "Memory Enhancement",
          "population_size_us": "TBD",
          "pathway": "Novel indication - pathway TBD",
          "precedent": "DARPA RAM program research"
        }
      ],
      "regulatory_challenges": [
        "DBS depression trials failed effectiveness endpoints",
        "Higher evidence bar for psychiatric indications",
        "Patient selection criteria critical"
      ]
    }
  ],
  "research_device_regulations": {
    "ruo_labeling": {
      "required_statement": "For Research Use Only. Not for use in diagnostic procedures.",
      "regulation": "21 CFR 809.10(c)",
      "restrictions": [
        "Cannot be promoted for clinical use",
        "Cannot make diagnostic or treatment claims",
        "Cannot be distributed for clinical purposes"
      ]
    },
    "ide_exemptions": {
      "regulation": "21 CFR 812.2(c)",
      "exempt_categories": [
        "Legally marketed device used according to labeling",
        "Device for veterinary use",
        "Device shipped solely for research on laboratory animals",
        "Custom device as defined in 21 CFR 812.3(b)",
        "Device undergoing consumer preference testing"
      ]
    },
    "non_significant_risk": {
      "description": "Abbreviated IDE pathway for lower-risk studies",
      "requirements": [
        "IRB determines device is NSR",
        "No FDA IDE submission required",
        "Still requires IRB approval and informed consent",
        "Sponsor must comply with labeling and record-keeping"
      ],
      "not_applicable_to": "Implantable neural devices (typically SR)"
    }
  },
  "visual_prosthesis_landscape": {
    "approved_devices": [
      {
        "name": "Argus II",
        "company": "Second Sight",
        "type": "Retinal prosthesis",
        "electrodes": 60,
        "pathway": "HDE",
        "approval_date": "2013-02",
        "status": "Discontinued (company bankruptcy)"
      }
    ],
    "in_development": [
      {
        "name": "Orion",
        "company": "Cortigent (formerly Second Sight)",
        "type": "Cortical visual prosthesis",
        "electrodes": 60,
        "status": "Early Feasibility Study",
        "nct": "NCT03344848"
      },
      {
        "name": "Neuralace Visual",
        "company": "Blackrock Neurotech",
        "type": "High-density cortical prosthesis",
        "electrodes": 10000,
        "status": "Preclinical",
        "target_first_human": 2028
      }
    ],
    "key_regulatory_considerations": [
      "Long-term implant requires extensive biocompatibility testing",
      "Visual cortex stimulation is significant risk",
      "Small patient population favors HDE pathway",
      "Post-market surveillance likely required"
    ]
  },
  "mental_health_device_landscape": {
    "tms_precedents": [
      {
        "device": "NeuroStar",
        "company": "Neuronetics",
        "indication": "MDD",
        "pathway": "510(k)",
        "k_number": "K083538",
        "year": 2008
      },
      {
        "device": "Brainsway DTMS",
        "company": "Brainsway",
        "indication": "OCD",
        "pathway": "De Novo",
        "den_number": "DEN170078",
        "year": 2018
      },
      {
        "device": "SAINT",
        "company": "Magnus Medical",
        "indication": "Treatment-resistant depression",
        "pathway": "510(k)",
        "year": 2022
      }
    ],
    "dbs_precedents": [
      {
        "device": "Reclaim",
        "company": "Medtronic",
        "indication": "OCD",
        "pathway": "HDE",
        "year": 2009,
        "notes": "Only approved psychiatric DBS indication"
      }
    ],
    "dbs_depression_failures": [
      {
        "trial": "BROADEN",
        "target": "Subcallosal cingulate (Area 25)",
        "outcome": "Failed to meet primary endpoint",
        "year": 2017
      },
      {
        "trial": "RECLAIM",
        "target": "Ventral capsule/ventral striatum",
        "outcome": "Failed to meet primary endpoint",
        "year": 2015
      }
    ],
    "implications_for_neuralace": [
      "Non-invasive TMS has easier regulatory path than invasive DBS",
      "DBS depression trials failed - high bar for invasive approaches",
      "OCD HDE provides model for severe, treatment-resistant cases",
      "Patient selection and trial design critical for success"
    ]
  }
}
